Clinical stage 3 non-small-cell lung cancer NSCLC inoperable
Conditions
Interventions
Intensity modulated radiotherapy, chemotherapy
Concurrent chemoradiotherapy, IMRT
Sponsors
Harada Hideyuki
Nishimura Yasumasa
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Non-small cell lung cancer(NSCLC) diagnosed by cytological or histological examination 2)Inoperable 3)Clinical stage 3 NSCLC, possible for definitive radiotherapy 4)No previous chemotherapy or radiotherapy 5)Measurable lesions 6)Age; 20 -75 years old 7)ECOG performance status:0-1 8)Ingestible 9)Sufficient function in bone marrow, heart, lung, liver and kidney 10)Written informed consent
Exclusion criteria
Exclusion criteria: 1)Active double cancer 2)Severe infection or morbidity 3)HBs antigen positive 4)Previous thoracic radiotherapy 5)Interstitial pneumonia or fibrosis on CT 6)Severe emphysema or chronic bronchitis or asthma 7)Severe drug allergy 8)Severe diabetes 9)Unstable angina or myocardial infarction within 6 months 10)Febrile more than or equal to 38 degree 11)Systemic use of corticosteroid or immunosuppressive drug 12)Expectant mother or breast feeding woman or not agreed with contraception 13)Psychiatric disorder 14)Unsuitable for enrollment judged by attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Completion rate of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, Progression free survival, Toxicities | — |
Contacts
Public ContactHideyuki Harada
Shizuoka Cancer Center
Outcome results
None listed